Israel Englander Tempest Therapeutics, Inc. Transaction History

Millennium Management LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$0.7 - $1.45 $132,654 - $274,783	189,506 New	189,506 $159,000
Q2 2023 Aug 14, 2023	SELL	$1.12 - $3.76 $7,241 - $24,312	-6,466 Reduced 38.49%	10,331 $13,000
Q1 2023 May 15, 2023	BUY	$1.14 - $2.91 $19,148 - $48,879	16,797 New	16,797 $39,000
Q3 2022 Nov 14, 2022	SELL	$1.62 - $2.76 $4,391 - $7,482	-2,711 Reduced 19.82%	10,964 $19,000

1.38M

42.8K

72.9K

Ticker TPST
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,418,900
Market Cap $91M
Description
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxiso...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.